Aurobindo Pharma Limited = RESULTS = Q 3 FY 2011 = QTR ENDING DECEMBER 2010 = CONSOLIDATED NPT UP BY 9.8%

Aurobindo Pharma Limited

NSE Symbol AUROPHARMA

Aurobindo Pharma has declared consolidated results for third quarter ending December, 201o.

NET SALES  is Rs.1192 cr – up by 7.15% from Q2 FY 2011 and up by 30.26% from Q3 FY 2010.

Total Expenditure is Rs.912 cr – up by 10.82% fromQ2 FY 2011 and up by 29.05% from Q3 FY 2010.

Profit from Operations is Rs.280 Cr – down by 3.28% from Q2 FY 2011 and UP by 34.33% from Q3 FY 2010.

Consolidated Net Profit is Rs.189 cr – down by 4.89% fromQ2 FY 2011 and up by 9.8% from Q3 FY 2010.

Basic EPS is Rs.32.4 compared to Rs.34.37 in Q2 FY 2011 and Rs.31.9 in Q3 FY 2010.

RESULTS TABLE :

AUROBINDO PHARMA	Q3 FY 11	Q2 FY 11	Q3 FY 10
Net Sales	119220	111262	91524
DIF %1	1192	7.15	30.26
Incre./Decre. in SIT / WIP	-10687	-3215	-9770
Raw Materials	63609	55364	47157
Traded goods	4161	3327	3528
Employees Cost	10804	10737	9013
Depreciation	4335	4071	4037
Other Expenditure	18977	12008	16710
Total Expenditure	91199	82292	70670
DIF %2	912	10.82	29.05
Profit from Operations	28021	28970	20860
DIF %3	280	-3.28	34.33
Other Income	588	1058	370
Interest	1146	1927	1270
Profit before tax	27463	28101	22440
Tax Expense	7825	8297	5490
Net Profit	18872	19804	17180
Consolidated Net Profit	18863	19832	17177
DIF %4	189	-4.89	9.8
Face Value (in Rs.)	5	5	5
Paid-up Equity	2911.2	2911	2700
Basic EPS	32.4	34.37	31.9
Diluted EPS	29.18	30.92	26.57

"We continue to see a strong momentum in our formulations business with the scaling up of operations of the large formulations units in Jedcherla SEZ near Hyderabad, India and New Jersey, USA," the company  said in a statement.

The Hyderabad-based company filed 15 abbreviated new drug applications (ANDA) during the third quarter taking the cumulative filings to 200.

Aurobindo Pharma, during the quarter, has also filed 54 dossier filings in Europe, taking the cumulative filings to 906.

Last month, the company had announced to divest nearly 80 per cent of its stake in its loss-making Chinese subsidiary Aurobindo (Datong) Bio Pharma Co Ltd (ADBPL) to China National Pharmaceutical Group Corporation (Sinopharm).

 *  *  *   E  N   D   *   *  *